Drawing on his tenure as FDA Commissioner and his current work leading Nucleus RadioPharma, Dr. Hahn will share his perspective on how AI is reshaping drug development across clinical trials and regulatory submissions, and what sponsors need to understand as they incorporate AI into regulated workflows.